Chitkala Kalidas, Ph.D.
Dr. Kalidas is vice president and head of global regulatory affairs for oncology and in vitro diagnostics at Bayer. She leads a team of global regulatory strategists who are responsible for developing appropriate global strategies for programs in all stages of drug development and for the registration of in vitro diagnostics. Programs in her group include VITRAKVI® (larotrectinib), STIVARGA® (regorafenib), XOFIGO® (Radium-223), ALIQOPA® (copanlisib), NEXAVAR® (sorafenib) and darolutamide, among others.
Precision medicine is an area of interest for her group as well as novel development strategies including tissue agnostic development, novel clinical trial designs, pediatric development in oncology, and drug development in special populations. She has more than 18 years of experience in drug development. Prior to joining Bayer, Dr. Kalidas was at Merck & Co. Inc. where she worked across multiple therapeutic areas and geographic regions.
Prior to joining the pharmaceutical industry, she was a management consultant at the Boston Consulting Group. She has a Ph.D. in microbiology from Cornell University.